HISUN(SH:600267) Shang Hai Zheng Quan Bao·2025-04-22 21:23Core Viewpoint - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its drug, Dihydrosulfonyladenosine Methionine Enteric-Coated Tablets, which has passed the consistency evaluation for generic drug quality and efficacy [1][2]. Group 1: Drug Information - The drug is named Dihydrosulfonyladenosine Methionine Enteric-Coated Tablets, in tablet form, with a specification of 0.5g [1]. - The original product was developed by Abbott, and the main domestic manufacturers include Hai Zheng Pharmaceutical and Zhejiang Prolong Pharmaceutical Co., Ltd. [2]. - The global sales of Dihydrosulfonyladenosine Methionine Enteric-Coated Tablets are projected to be approximately $17.04 million in 2024, with domestic sales around $3.84 million [2]. Group 2: Financial Investment - The company anticipates a sales revenue of approximately 145 million RMB for the Dihydrosulfonyladenosine Methionine Enteric-Coated Tablets in 2024 [2]. - The company has invested about 25.23 million RMB in the consistency evaluation for this drug [2]. Group 3: Market Impact - The approval of the drug through the consistency evaluation is expected to enhance its market share and competitiveness due to increased support in medical insurance payments and procurement by medical institutions [4].